GALECTIN THERAPEUTICS INC (GALT) Stock Price, Quote, News and Overview
NASDAQ:GALT - Nasdaq - US3632252025 - Common Stock - Currency: USD
GALT Quote, Performance and Key Statistics
1.49
+0.02 (+1.36%)
The current stock price of GALT is 1.49 USD. In the past month the price increased by 21.14%. In the past year, price decreased by -20.74%.
GALT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GALT
Company Profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 14 full-time employees. The company went IPO on 2002-09-04. The firm's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The firm's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Company Info
GALECTIN THERAPEUTICS INC
Suite 240, 4960 Peachtree Industrial Boulevard
Norcross GEORGIA 30071 US
CEO: Joel Lewis
Employees: 14
Company Website: https://galectintherapeutics.com/
Investor Relations: https://investor.galectintherapeutics.com/
Phone: 16786203186
GALECTIN THERAPEUTICS INC / GALT FAQ
What is the stock price of GALECTIN THERAPEUTICS INC today?
The current stock price of GALT is 1.49 USD. The price increased by 1.36% in the last trading session.
What is the ticker symbol for GALECTIN THERAPEUTICS INC stock?
The exchange symbol of GALECTIN THERAPEUTICS INC is GALT and it is listed on the Nasdaq exchange.
On which exchange is GALT stock listed?
GALT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GALECTIN THERAPEUTICS INC stock?
6 analysts have analysed GALT and the average price target is 11.22 USD. This implies a price increase of 653.02% is expected in the next year compared to the current price of 1.49. Check the GALECTIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GALECTIN THERAPEUTICS INC worth?
GALECTIN THERAPEUTICS INC (GALT) has a market capitalization of 92.84M USD. This makes GALT a Micro Cap stock.
How many employees does GALECTIN THERAPEUTICS INC have?
GALECTIN THERAPEUTICS INC (GALT) currently has 14 employees.
What are the support and resistance levels for GALECTIN THERAPEUTICS INC (GALT) stock?
GALECTIN THERAPEUTICS INC (GALT) has a support level at 1.32 and a resistance level at 1.54. Check the full technical report for a detailed analysis of GALT support and resistance levels.
Should I buy GALECTIN THERAPEUTICS INC (GALT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GALT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GALT, evaluating the profitability, health, valuation and growth aspects
- GALECTIN THERAPEUTICS INC (GALT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GALECTIN THERAPEUTICS INC (GALT) Sales and EPS estimates to see what analysts future expectations are.
- GALECTIN THERAPEUTICS INC (GALT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GALECTIN THERAPEUTICS INC (GALT) Insider and Institutional Ownership to learn about the owners and their transactions.
- GALECTIN THERAPEUTICS INC (GALT) Stock Chart to make your own analysis
- GALECTIN THERAPEUTICS INC (GALT) Latest news and press-releases to stay up to date.
Does GALECTIN THERAPEUTICS INC (GALT) stock pay dividends?
GALT does not pay a dividend.
When does GALECTIN THERAPEUTICS INC (GALT) report earnings?
GALECTIN THERAPEUTICS INC (GALT) will report earnings on 2025-03-27, after the market close.
What is the Price/Earnings (PE) ratio of GALECTIN THERAPEUTICS INC (GALT)?
GALECTIN THERAPEUTICS INC (GALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
What is the Short Interest ratio of GALECTIN THERAPEUTICS INC (GALT) stock?
The outstanding short interest for GALECTIN THERAPEUTICS INC (GALT) is 18.64% of its float. Check the ownership tab for more information on the GALT short interest.
GALT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GALT. When comparing the yearly performance of all stocks, GALT is a bad performer in the overall market: 91.71% of all stocks are doing better.
GALT Financial Highlights
Over the last trailing twelve months GALT reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 3.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -156.12% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GALT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to GALT. The Buy consensus is the average rating of analysts ratings from 6 analysts.